Medical and interventional therapies for inoperable CTEPH: a necessary combination?
- PMID: 35926545
- DOI: 10.1016/S2213-2600(22)00227-2
Medical and interventional therapies for inoperable CTEPH: a necessary combination?
Conflict of interest statement
H-AG reports lecture fees and fees for advisory board and steering committee participation from Bayer, GlaxoSmithKline, Janssen/Actelion, and Pfizer; and fees for advisory board and steering committee participation from Aerovate, Altavant, Gossamer Bio, and MSD/Acceleron, outside of the submitted work. NHK reports grants from Altavant, Gossamer Bio, and SoniVie; lecture fees and fees for advisory board and steering committee participation from Janssen/Actelion; fees for advisory board and steering committee participation from Bayer and MSD/Acceleron; and fees for steering committee participation from United Therapeutics/Arena.
Comment in
-
Standards for assessing and reporting adverse events.Lancet Respir Med. 2022 Dec;10(12):e110-e111. doi: 10.1016/S2213-2600(22)00444-1. Epub 2022 Nov 11. Lancet Respir Med. 2022. PMID: 36375481 No abstract available.
Comment on
-
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.Lancet Respir Med. 2022 Oct;10(10):961-971. doi: 10.1016/S2213-2600(22)00214-4. Epub 2022 Aug 1. Lancet Respir Med. 2022. PMID: 35926542 Clinical Trial.
-
Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial.Lancet Respir Med. 2022 Oct;10(10):949-960. doi: 10.1016/S2213-2600(22)00171-0. Epub 2022 Aug 1. Lancet Respir Med. 2022. PMID: 35926544 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
